Is it difficult to get reimbursement from medical insurance for pomalidomide?

Pomalidomide is an immunomodulatory anti-tumor drug that is an improved and upgraded version of lenalidomide and thalidomide. It is mainly used to treat multiple myeloma (MM) and some relapsed or refractory hematological tumors. In recent years, with the accelerated reform of the domestic drug review and approval system, the original drug pomalidomide has been officially launched in China and included in the national medical insurance catalog. The implementation of this policy has undoubtedly greatly improved the accessibility of drugs and also reduced the financial burden of long-term treatment patients.

Although the drug has entered the medical insurance system, patients will still find that its reimbursement policies vary in different regions. Details such as the medical insurance reimbursement ratio, limited hospital scope, and prescription qualifications in each province and city are formulated by the local medical insurance department based on the fiscal budget and drug hierarchical management system. Therefore, the "difficulty in reimbursement" is more reflected in differences in procedures and policies, rather than the inability to reimburse the drug itself. At present, the reimbursement ratio in most areas ranges from about 50% to 70%, but it needs to be purchased at designated medical institutions with a doctor's prescription. Since pomalidomide is a prescription targeted drug, its use must be evaluated by a doctor and comply with medical insurance restrictions, such as "use after lenalidomide treatment fails", etc.

On an economic level, the price of pomalidomide’s original drug is still relatively expensive. Even after it is included in medical insurance, patients’ out-of-pocket costs are still high. The specifications sold in domestic pharmacies are mainly 2mg and 4mg capsules, and the price will change according to the dosage and course of treatment. For patients who need to take medicine for a long time, although the support of medical insurance policies can partially alleviate the pressure, they still need to pay attention to details such as the scope of local medical insurance reimbursement and whether they are included in the hospital drug catalog.

It is worth mentioning that generic pomalidomide drugs have appeared in some overseas markets with relatively low costs, providing more choices for patients around the world.

Reference materials:https://en.wikipedia.org/wiki/Pomalidomide